[Pulmonary fibrosis after a new coronavirus infection - versions and controversies: A review]
E I Shchepikhin1,2, E I Shmelev1, A E Ergeshov1
1Central Tuberculosis Research Institute.
Terapevticheskii Arkhiv
|May 7, 2024
Summary
Fibrosis, an overactive connective tissue repair, can cause lung damage after COVID-19. Understanding fibrogenesis post-infection is crucial for managing long-term lung health and interstitial lung disease prognosis.
Area of Science:
- Pulmonology
- Pathology
- Immunobiology
Background:
- Fibrosis involves excessive extracellular matrix accumulation, impacting disease pathogenesis and prognosis.
- Interstitial lung diseases (ILDs) are significantly influenced by fibrotic processes.
- COVID-19 frequently causes significant lung parenchyma involvement, raising concerns about long-term sequelae.
Purpose of the Study:
- To examine fibrogenesis in patients post-COVID-19.
- To correlate fibrogenesis with immunobiology, clinical course, and prognosis.
- To understand the link between COVID-19 lung damage and interstitial lung disease development.
Main Methods:
- Review of existing literature on fibrogenesis.
- Analysis of data from a Russian registry (ClinicalTrials.gov: NCT04492384).
- Examination of immunobiological and clinical data of post-COVID-19 patients.
Main Results:
- A significant portion of COVID-19 patients exhibit extensive lung damage (>50%).
- Long-term clinical and functional changes post-COVID-19 resemble other interstitial lung diseases.
- Fibrosis progression is a key determinant of prognosis in these patients.
Conclusions:
- COVID-19 can lead to fibrotic lung changes similar to idiopathic interstitial pneumonias.
- Understanding fibrogenesis is critical for managing post-COVID-19 lung complications.
- Further research into the immunobiology of post-COVID-19 fibrosis is warranted for improved patient outcomes.
Keywords:
fibrosisimmunologyinterstitial lung diseasespost-COVIDprogressive fibrotic phenotypepulmonary functionMore Related Videos
08:05Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
14.1K
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
144
Related Concept Videos
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:29Pneumonia II: Pathophysiology
260
The pathophysiology of pneumonia involves the following steps:
260
01:21Acute Respiratory Failure-II
217
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
217
01:28Pneumonia IV: Management
323
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
323
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:20COPD: Pathogenesis and Clinical Features
263
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
263